Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Apoorva Ambavane
Observed names:
A Ambavane,
A. Ambavane,
Ambavane, Apoorva
Institution:
CMCL Innovations (United Kingdom)
Observed institutions:
University of Iowa,
University of Massachusetts Chan Medical School,
Developmental Studies Hybridoma Bank,
Indiana University Bloomington,
University of Pittsburgh Medical Center,
CMCL Innovations (United Kingdom),
Texas A&M University
show all 7
ORCID:
0000-0001-5887-792X
Observed ORCID:
0000-0001-5887-792X
OpenAlex ID:
A5056195662
Sialyltransferase Regulates Nervous System Function in Drosophila
2010
·
Elena Repnikova
, Kate Koles
, et al.
·
Journal of Neuroscience
·
79
PDF
Economic evaluation of the one-hour rule-out and rule-in algorithm for acute myocardial infarction using the high-sensitivity cardiac troponin T assay in the emergency department
2017
·
Apoorva Ambavane
, Bertil Lindahl
, et al.
·
PLoS ONE
·
73
PDF
Correction: Economic evaluation of the one-hour rule-out and rule-in algorithm for acute myocardial infarction using the high-sensitivity cardiac troponin T assay in the emergency department
2018
·
Apoorva Ambavane
, Bertil Lindahl
, et al.
·
PLoS ONE
·
39
PDF
Clinical and Economic Outcomes Associated with Treatment Sequences In Patients With BRAF -Mutant Advanced Melanoma
2018
·
Ahmad Tarhini
, David McDermott
, et al.
·
Immunotherapy
·
35
PDF
Sequential Treatment Approaches in the Management of BRAF Wild-Type Advanced Melanoma: A Cost–Effectiveness Analysis
2018
·
Ahmad Tarhini
, Agnes Benedict
, et al.
·
Immunotherapy
·
27
PDF
Treatment sequences for advanced renal cell carcinoma: A health economic assessment
2019
·
Baris Deniz
, Apoorva Ambavane
, et al.
·
PLoS ONE
·
23
PDF
Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis
2018
·
D.F. McDermott
, B.I. Rini
, et al.
·
Annals of Oncology
·
22
Clinical and Economic Outcomes of Treatment Sequences for Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma
2020
·
Apoorva Ambavane
, Shuo Yang
, et al.
·
Immunotherapy
·
17
PDF
Survival Analysis in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
2019
·
Tereza Lanitis
, Irina Proskorovsky
, et al.
·
Advances in Therapy
·
16
PDF
Cost-effectiveness analysis of second-line tyrosine kinase inhibitor treatment for chronic myelogenous leukemia
2015
·
John Whalen
, Ipek Stillman
, et al.
·
Journal of Medical Economics
·
16
PDF
Budget impact of tepotinib in the treatment of adult patients with metastatic non-small cell lung cancer harboring METex14 skipping alterations in the United States
2021
·
Matthew Stargardter
, Ali McBride
, et al.
·
Journal of Medical Economics
·
9
Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis
2021
·
Andreas Nikolaou
, Apoorva Ambavane
, et al.
·
Expert Review of Hematology
·
7
Value Assessment of Immuno-Oncology in the Treatment of Rare Tumors in the Era of Accelerated Conditional Approvals
2019
·
Tereza Lanitis
, Apoorva Ambavane
, et al.
·
Future Oncology
·
6
ESMO-MCBS and health technology assessment (HTA): Does value for physicians correspond to value for payers?
2019
·
A. Ambavane
, A. Benedict
, et al.
·
Annals of Oncology
·
6
Cost-effectiveness of regorafenib for pretreated metastatic colorectal cancer patients in the United States.
2013
·
Brian S. Seal
, Ipek Özer-Stillman
, et al.
·
Journal of Clinical Oncology
·
6
Comprehensive Reporting in Cost-Effectiveness Modeling
2017
·
Ágnes Benedict
, Apoorva Ambavane
, et al.
·
Journal of Clinical Oncology
·
5
Clinical and economic outcomes associated with sequential treatment in BRAF mutant advanced melanoma patients.
2018
·
Ahmad A. Tarhini
, David F. McDermott
, et al.
·
Journal of Clinical Oncology
·
4
Modeling health outcomes associated with BRCA testing and treatment strategies for patients with metastatic pancreatic cancer
2024
·
Neeharika Agnihotri
, Apoorva Ambavane
, et al.
·
Pancreatology
·
3
A Cost-Effectiveness Analysis of Axitinib and Sorafenib for 2nd Line Treatment of Advanced Renal Cell Carcinoma After Failure of Cytokines in the United States
2013
·
I.O. Stillman
, A. Ambavane
, et al.
·
Value in Health
·
3
Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States
2021
·
Anshul Shah
, Jonathan C Tosh
, et al.
·
ClinicoEconomics and Outcomes Research
·
2
PDF
P-213 The cost of survival gain in metastatic colorectal cancer (mCRC) in Spain
2015
·
J. Whalen
, J. Chang
, et al.
·
Annals of Oncology
·
2
P-212 The cost of survival gain in metastatic colorectal cancer (mCRC) in France
2015
·
J. Whalen
, J. Chang
, et al.
·
Annals of Oncology
·
2
PDF
2814. The Impact of Novel Antibiotics on Curbing Antimicrobial Resistance and Infection Spread a Dynamic Modeling Study
2023
·
Apoorva Ambavane
, Michal Litkiewicz
, et al.
·
Open Forum Infectious Diseases
·
1
PDF
Financial impact of tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer bearing METex14 skipping in the United States.
2021
·
Matthew Stargardter
, Mo Yang
, et al.
·
Journal of Clinical Oncology
·
1
Application of dynamic modeling for survival estimation in advanced renal cell carcinoma
2018
·
Baris Deniz
, Arman Altincatal
, et al.
·
PLoS ONE
·
1
PDF
Show more works
View as search
Works count:
49
Citation count:
410
H-index:
10
I10-index:
10
Year
Topic
Type